TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Consensus Target Price from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $40.67.

Several analysts recently issued reports on TGTX shares. TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price on the stock. HC Wainwright boosted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, December 14th. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a report on Monday, November 25th. Finally, The Goldman Sachs Group upped their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th.

TG Therapeutics Trading Up 4.0 %

Shares of TG Therapeutics stock traded up $1.25 during trading on Friday, reaching $32.20. The company's stock had a trading volume of 2,793,497 shares, compared to its average volume of 3,586,359. The company has a market cap of $5.01 billion, a price-to-earnings ratio of -321.97 and a beta of 2.25. The firm's 50-day moving average is $29.42 and its two-hundred day moving average is $23.79. TG Therapeutics has a 52-week low of $12.84 and a 52-week high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's revenue was down 49.4% on a year-over-year basis. During the same period last year, the firm posted $0.73 EPS. On average, sell-side analysts anticipate that TG Therapeutics will post 0.17 earnings per share for the current year.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. NBC Securities Inc. raised its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in TG Therapeutics in the second quarter worth about $35,000. Blue Trust Inc. increased its stake in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 849 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics in the 3rd quarter valued at approximately $53,000. Finally, Values First Advisors Inc. purchased a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $58,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.